On May 14, 2026 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent Corporate Highlights and Upcoming Milestones

INBRX-106
In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combined Positive Score (CPS) ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
We plan to announce progression-free survival (PFS) data from the randomized Phase 2 trial in HNSCC in combination with pembrolizumab in the fourth quarter of 2026.
ozekibart (INBRX-109)
In April 2026, we announced updated interim data from our Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC);
Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ozekibart in conventional chondrosarcoma; and
We plan to meet with the FDA in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC. We also plan to discuss with the FDA the potential for accelerated regulatory pathways for ozekibart in fourth-line colorectal cancer and in refractory Ewing sarcoma.
Financial Results

Cash and Cash Equivalents. As of March 31, 2026, the Company had cash and cash equivalents of $161.7 million, as compared to $124.2 million as of December 31, 2025. The Company’s cash balance increased as a result of the receipt of gross proceeds of $75.0 million in March 2026 upon entering into the First Amendment to the Loan and Security Agreement (March 2026 Amendment) with Oxford Finance LLC (Oxford).
R&D Expense. Research and development expenses were $25.2 million for the first quarter of 2026, as compared to $36.9 million for the first quarter of 2025. This decrease was primarily related to lower clinical trial costs associated with ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma as the trial approached completion of enrollment, as well as a decrease in contract manufacturing expenses due to the timing and completion of certain manufacturing activities required to support our clinical trials. In addition, personnel-related expenses decreased as a result of a decrease in headcount in the current period.
G&A Expense. General and administrative expenses were $5.7 million during the first quarter of 2026, compared to $6.0 million during the first quarter of 2025. These expenses were consistent in each period with a slight decrease in personnel-related expenses as a result of a decrease in headcount in the current period.
Other Expense, Net. Other expense, net was $2.5 million during the first quarter of 2026, compared to $0.4 million during the first quarter of 2025. The increase reflects higher interest expense following the Company’s receipt of an additional $75.0 million in principal, bringing the outstanding loan balance from $100.0 million to $175.0 million during the first quarter of 2026, as well as lower interest income on the Company’s cash and money market balances reflecting lower average cash balances and a decline in short-term interest rates.
Net Loss. Net loss was $33.4 million during the first quarter of 2026, or $2.15 per share, basic and diluted, as compared to a net loss of $43.3 million during the first quarter of 2025, or $2.80 per share, basic and diluted.

(Press release, Inhibrx, MAY 14, 2026, View Source [SID1234665736])

On May 14, 2026 SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, reported that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This multi-center trial, conducted across sites globally including the United States and Europe, will enroll up to 135 patients. The study is designed in three sequential stages: a Phase 1b dose-escalation phase using a 3+3 design to determine the Maximum Tolerated Dose (MTD) at dose levels of 50–70 mg/m², followed by a two-part Phase 2 consisting of Phase 2a and Phase 2b. Phase 2a will conduct dose optimization to identify the optimal therapeutic dose, after which Phase 2b will proceed with dose expansion at the optimized dose to further evaluate clinical activity across a broader patient population. Across Phase 2, key efficacy endpoints including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) will be assessed to generate the clinical evidence necessary to support regulatory review process.

The advancement into Phase 2 is supported by encouraging prior Phase 1 results conducted in Korea, in which SNB-101 demonstrated a favorable safety profile with no Grade 3 or higher diarrhea events, a disease control rate (DCR) of 83.3% in high-dose cohorts, and a mean progression-free survival (PFS) of 6.3 months in SCLC patients. These findings compare favorably with outcomes historically reported for currently available later-line treatment options, including Zepzelca and Topotecan.

Based on its Phase 1 results, SNB-101 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for SCLC. Together with Orphan Drug Designation from the FDA and EMA, these designations reflect that SNB-101 has fully established the regulatory framework necessary to pursue accelerated approval.

As a monotherapy, SNB-101 has demonstrated encouraging clinical activity together with a favorable tolerability profile in previously treated SCLC patients. The company believes these findings support the continued clinical development of SNB-101 as a potential treatment option for patients with relapsed SCLC, particularly in later-line settings where tolerability and efficacy remain an important unmet need.

In parallel with the ongoing monotherapy program, SN BioScience is actively expanding the development of SNB-101 into combination strategies with immunotherapy agents (including anti-PD-1, anti-PD-L1, and DLL3-targeted BiTE T-cell engager therapies) currently used in standard SCLC treatment. The company has already obtained EMA approval for a clinical study evaluating SNB-101 in combination with one immunotherapy agent and is planning to submit an additional CTA within this year for a separate study involving another immunotherapy combination.

In addition, SN BioScience is pursuing the expansion of SNB-101 into additional solid tumor indications, including gastric and pancreatic cancers, through ongoing collaborations and strategic discussions with global pharmaceutical companies.

(Press release, SN BioScience, MAY 14, 2026, View Source [SID1234665735])

On May 14, 2026 Ring Therapeutics, a life sciences company pioneering a new class of targeted medicines, reported new data on its Vector Conjugate platform and VectorBricks in vitro manufacturing technology. The data, which are being presented as a poster and an oral presentation at the 29th Annual American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) conference, highlight significantly increased cargo capacity for the delivery of oligonucleotides using targetable vectors and VectorBricks as a scalable in vitro manufacturing platform for the modular production of novel vector conjugate medicines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Two distinct but related technical challenges have constrained the field of targeted therapeutics: payload ceiling and manufacturing complexity. Ring’s Vector Conjugate platform brings together distinct innovations in vector discovery, design, and engineering to expand payload capacity and improve cell and tissue targeting with the aim of unlocking new targets for drug delivery. Ring’s modular VectorBricks manufacturing technology spans multiple innovations to reduce the complexity of vector manufacturing to the simplicity of producing a single recombinant protein. With VectorBricks, Ring is able to make vectors and vector conjugates at greater cost efficiency and scale than existing technologies.

"Ring’s Vector Conjugate platform delivers orders of magnitude more payload than antibodies and can carry anything from small molecules to oligonucleotides," said Dmitriy Bobrovnikov, PhD, Chief Innovation Officer of Ring Therapeutics. "The data we are presenting at ASGCT (Free ASGCT Whitepaper) highlight how our vectors carry siRNA directly as Vector Oligo Conjugates (VOCs), as well as the underlying VectorBricks manufacturing technology that makes our platform uniquely possible."

Bobrovnikov continued, "Payload capacity is crucial to unlocking new tissues and targets for oligonucleotide therapy. Selective tissue targeting needs to move beyond the transferrin receptor to receptors that require more payload capacity to compensate for their lower expression levels. Our VOCs enable selective targeting and ultimately expand oligo-conjugate technology beyond rare genetic disorders."

Presentation details and key highlights below:

Poster Presentation:

Title: Vector Oligonucleotide Carriers (VOCs): A platform for targeted oligonucleotide delivery with redosable viral capsids
Abstract number: 3356

Presentation location, date, and time: Exhibit and Poster Hall (Halls B2-C), Thursday, May 14, 5:00 – 6:30 PM ET

This work introduces Vector Oligonucleotide Conjugates (VOCs), a novel modular platform for viral capsid–mediated delivery of oligonucleotides.
VOCs were successfully manufactured by direct conjugation of synthetic siRNA molecules onto recombinant capsid proteins followed by in vitro capsid assembly, with controllable surface decoration with targeting ligands at varying densities.
Conjugation of either a small targeting ligand (TL) or a targeting monoclonal antibody to the VOC surface drove robust internalization into target cells.
TL-conjugated VOCs delivered functional siRNA payloads that triggered specific target gene knockdown in vitro, with TL functionalization enhancing potency over untargeted VOC.
Oral Presentation:

Title: Pilot-scale production of in vitro assembled Anellovirus capsids to establish a novel therapeutic platform
Speaker: Sunaina Kiran Prabhu, PhD – Associate Director, Tech Ops at Ring Therapeutics

Session Title and Location: Vector manufacturing and analytics – Room 257AB (Level 2)

Presentation time: Thursday, May 14, 4:15 – 4:30 PM ET

The presentation outlines VectorBricksTM, a cost-effective, highly modular in vitro assembly platform that offers versatility in payload and targeting. It consists of two key building blocks: a recombinant capsid protein and a therapeutic payload.
Recombinant Anellovirus capsid protein was produced in high titers, achieving cell-specific productivity levels comparable to traditional monoclonal antibody processes.
The robustness and scalability of this process was demonstrated at a 50-liter scale.
Purified pentamer building blocks were assembled in vitro into monodisperse capsid particles with high yields.
This modular platform was shown to successfully package diverse payloads including small molecules, siRNA and DNA.

(Press release, Ring Therapeutics, MAY 14, 2026, View Source;cell-therapy-conference-302771719.html [SID1234665734])

On May 14, 2026 CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, reported the closing of its $122 million Series B funding round, co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current members of CREATE’s investor syndicate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funding will support advancement of CREATE’s clinical pipeline across autoimmune disease and oncology. To date, CREATE has dosed more than 50 patients across its in vivo CAR clinical programs — the largest clinical dataset in the field — generating the translational foundation that informs development across both autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform programs immune cells directly inside the body, enabling a rapid, iterative product engine designed to compress concept-to-clinic timelines.

In autoimmune, CREATE’s lead program CRT-402, a next generation CD19 targeted in vivo CAR-T therapy, has demonstrated deep and durable B cell depletion in non-human primates, with the potential to enable immune reset through the flexibility of repeat dosing. The company is also advancing a dual CAR CD19 x BCMA directed therapy designed to broaden therapeutic reach across refractory autoimmune indications.
In oncology, CREATE continues to advance therapies focused on areas of high unmet need. Early clinical data from the company’s MT-303 program in frontline hepatocellular carcinoma has demonstrated an extremely compelling response profile.
Collectively, these programs exemplify CREATE’s iterative platform that integrates clinically validated CAR architectures, optimized RNA design, and targeted delivery technologies with deep expertise across clinical development, translational medicine, manufacturing, and regulatory execution.
"CREATE was built as an iterative immune programming platform in which each clinical study informs and strengthens the next, and it is that work that has revealed the breadth of what in vivo immune programming can address," said Daniel Getts, PhD, Chief Executive Officer of CREATE Medicines. "Our autoimmune and oncology pipeline represents the convergence of years of platform development, clinical execution, and translational learning. We believe our ability to engineer multiple immune cell populations directly in vivo has the potential to fundamentally reshape treatment paradigms across autoimmune disease and oncology, and we look forward to this next chapter of innovation and growth."

In conjunction with the Series B Round, Ron Philip, a veteran biopharma leader, has joined CREATE as Executive Chairman. Brian Cuneo, Senior Partner at ARCH Venture Partners, and Tom Thomas, PhD of Newpath Partners, have joined the company’s Board of Directors.

"I’m excited to join CREATE at this pivotal moment in the company’s evolution," said Ron Philip. "CREATE has established meaningful in vivo clinical proof points and built a differentiated immune programming platform with the potential to redefine how engineered immune therapies are developed and delivered. The opportunity to translate these capabilities into transformative medicines across autoimmune disease and oncology is exceptionally compelling."

"I co-founded this company because the science was ahead of the field. More than fifty patients later, it still is. Most in vivo cell therapy companies will struggle to translate science into scalable manufacturing. CREATE owns its manufacturing infrastructure. I am backing CREATE because it can become the next great standalone pharmaceutical company," said Tom Cahill, MD, PhD, Founder and Managing Partner of Newpath Partners.

"CREATE is building one of the most differentiated in vivo immune engineering platforms in the field," said Brian Cuneo. "We believe the company’s clinical experience, repeat dose strategy, and broad immune programming capabilities position it to play an important role in the future of autoimmune disease and oncology."

(Press release, Create Medicines, MAY 14, 2026, View Source [SID1234665733])

On May 14, 2026 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, reported that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company’s investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocrine therapy backbone across multiple estrogen receptor ("ER") -positive breast cancer settings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature internationally recognized surgical oncologist and breast cancer expert Dr. Laura Esserman. Dr. Esserman serves as Director of the University of California San Francisco Breast Care Center and is the founder and principal investigator of the I-SPY Trials, an innovative platform designed to accelerate the development of personalized breast cancer therapies.

"Dr. Esserman has been at the forefront of innovation in breast cancer clinical research, adaptive trial design, and precision oncology for decades," said Dr. Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer of Atossa Therapeutics. "We believe (Z)-endoxifen has the potential to become more than a single-indication therapy; it may serve as an endocrine therapy platform across multiple ER-positive breast cancer settings. Dr. Esserman’s leadership in translational breast cancer research makes her an ideal expert to discuss the emerging clinical and biomarker data supporting this opportunity."

The discussion is expected to address several topics of interest to clinicians, investors, and potential strategic partners, including:

Recent data from the I-SPY2 Endocrine Optimization Pilot study evaluating (Z)-endoxifen as monotherapy in newly diagnosed ER-positive breast cancer patients
Translational biomarker data, including Ki-67 reduction, MRI functional tumor volume changes, and circulating tumor DNA dynamics
Data supporting (Z)-endoxifen activity across clinically relevant ESR1 mutations, including Y537N, Y537S, and D538G
The rationale for (Z)-endoxifen as a potential next-generation endocrine therapy backbone
Combination strategies, including CDK4/6 inhibitor combinations
Development opportunities in premenopausal breast cancer and endocrine therapy optimization
Event Details

Date: Tuesday, May 19, 2026
Time: 1:00 to 2:00 p.m. PT
Moderator: Michael King, Managing Director at Rodman & Renshaw
Registration: View Source

Attendees may submit questions to [email protected] up to 24 hours prior to the event.

A replay of the webcast will be available on the Company’s "Investors" portion of its website for at least 60 days following the live event.

About (Z)-Endoxifen

(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader, or SERM/D, with demonstrated activity across multiple mechanisms of action. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-endoxifen is not approved for any indication.

(Press release, Atossa Therapeutics, MAY 14, 2026, View Source [SID1234665732])